Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 9, 2014 - Issue 3
Submit an article Journal homepage
558
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects

Denis RaccahDepartment of Diabetology, University Hospital Sainte Marguerite, 270 Boulevard de Sainte Marguerite, 13009 Marseille, FranceCorrespondence[email protected]
Pages 201-203 | Published online: 31 Mar 2014

References

  • Raccah D. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. Expert Rev Endocrinol Metab 2013;8(2):105-21
  • Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27(9):1024-32
  • Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164(2-3):58-64
  • Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307(2):490-6
  • Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117(2):77-88
  • Schwahn U, Stengelin S, Werner U. Functional activity of lixisenatide and GLP-1 receptor expression in in-vitro thyroid C-cells of rat and human origin. Diabetes 2013;62(Suppl 1):A259
  • Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia. Regul Pept 2013;185C:1-8
  • Kapitza C, Coester HV, Berria R, et al. Pharmacodynamic profiles of lixisenatide vs. liraglutide in patients with type 2 diabetes mellitus on metformin. International Diabetes Federation; 2013. P-1066
  • Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15(7):642-9
  • Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia 2012;55(5):1283-90
  • Sanofi-Aventis. Lyxumia EMA submission. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf
  • Victoza liraglutide. Product mongraphy. Available from: http://www.novonordisk.ca/PDF_Files/VictozaProductMonographEnglish.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.